

**REMARKS**

This is a response to the Office Communication mailed December 26, 2006 (**Non-Final Action**). The three-month extended deadline for filing a response is June 26, 2007. Applicants submit herewith a three-month Petition for Extension of Time and the appropriate fee. Therefore, Applicants believe that this response is being timely filed. Applicants believe that the fees submitted herewith are sufficient. However, in the event that Applicants are incorrect in their assumption, please charge any necessary fee to Deposit Account No. 23-2415, referencing Docket No. 31747-706.201.

At the outset, Applicants note with appreciation the indication in the Office Action that Claims 2-4 are allowable. In view of the above amendments and the foregoing remarks, Applicants respectfully submit that all the claims now in that application are in condition for allowance, such favorable action is earnestly solicited.

By the above amendments, Claim 1 has been revised to more clearly set forth an embodiment of the invention wherein the laminin selective peptide antagonist comprises the sequence S-T-Q and binds with substantially greater affinity to denatured laminin than to native laminin. This amendment is supported throughout the specification, See, for example, the discussion in connection with Examples 4-6.

New Claims 37-39 have been added to round out certain embodiments of the elected invention. The newly added claims recite a denatured laminin selective peptide antagonist comprising the sequence L-S-L-T-V wherein said laminin selective peptide antagonist binds with substantially greater affinity to denatured laminin than to native laminin. The newly added claims are supported through out the specification. See, for example, the discussion of selected laminin selective antagonists on page 6 of the Specification as originally filed.

Accordingly, it is believed that the above amendments raise no new issues. Entry of the amended claims is proper and such action is respectfully requested.

Turning to the Office Action, Claims 1 and 5-11 were rejected under 35 U.S.C. 112, first paragraph, as allegedly failing to comply with the written description requirement. This rejection is traversed in as much as it is applied to the amended claims now in the application.

In order to expedite allowance of the application, Applicants have amended the claims to recite a laminin selective peptide antagonist comprising the sequence S-T-Q and binds with

substantially greater affinity to denatured laminin than to native laminin. The Specification provides ample support for the amended claims. Accordingly, withdrawal of the rejection under the first paragraph of the patent statute is respectfully requested.

**CONCLUSION**

In view of the remarks and amendments submitted herein, Applicants believe that the Application is in condition for allowance and such favorable action is earnestly solicited.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (858) 350-2337.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI  
Professional Corporation



Dated: June 26, 2007

Samir Elamrani, Ph.D. Agent for Applicants  
Registration No. 43,601

WILSON SONSINI GOODRICH & ROSATI  
650 Page Mill Road  
Palo Alto, CA 94304-1050  
Direct Dial: (858) 350-2337  
Customer No. 21971